产品说明书

Cefdinir

Print
Chemical Structure| 91832-40-5 同义名 : CI-983;FK-482;BMY 28488;PD 134393
CAS号 : 91832-40-5
货号 : A123828
分子式 : C14H13N5O5S2
纯度 : 98%
分子量 : 395.413
MDL号 : MFCD00865030
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 35 mg/mL(88.51 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Cefdinir is a third-generation cephalosporin with a broad spectrum of antibacterial activity encompassing pathogens that are commonly causative in infections of the respiratory tract or skin and skin structure. Cefdinir is stable to hydrolysis by commonly occurring plasmid-mediated beta-lactamases and retains good activity against beta-lactamase-producing strains of H. influenzae and M. catarrhalis[3]. Subjects assigned to cefdinir exhibited notable, improvements in tic symptoms, compared with the placebo group[4]. Moreover, cefdinir inhibited Gly-Sar uptake, but with low affinity, resulting in 50% inhibitory concentrations (or Ki values) on the order of 10 to 20 mM for both transporters (PEPT1 and PEPT2)[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01511107 Acute Otitis Media Phase 2 Terminated(The primary objecti... 展开 >>ve of the study was met.) 收起 << - United States, Kentucky ... 展开 >> Kentucky Pediatric/Adult Research Bardstown, Kentucky, United States, 40004 United States, Pennsylvania Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 收起 <<
NCT01734759 Healthy Phase 1 Completed - United States, Minnesota ... 展开 >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 收起 <<
NCT01511107 - Terminated(The primary objecti... 展开 >>ve of the study was met.) 收起 << - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.65mL

2.53mL

1.26mL

25.29mL

5.06mL

2.53mL
参考文献

[1]Lepsy CS, Guttendorf RJ, et al. Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney. Antimicrob Agents Chemother. 2003 Feb;47(2):689-96.

[2]Labro MT, el Benna J, et al. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol. 1994 Mar 1;152(5):2447-55.

[3]Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs. 2004;64(13):1433-64.

[4]Murphy TK, Parker-Athill EC, Lewin AB, Storch EA, Mutch PJ. Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial. J Child Adolesc Psychopharmacol. 2015 Feb;25(1):57-64.

[5]Lepsy CS, Guttendorf RJ, Kugler AR, Smith DE. Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney. Antimicrob Agents Chemother. 2003 Feb;47(2):689-96.